NCT02966353 - Efficacy and Safety of Ruxolitinib in the Treatment of Anemic Myelofibrosis Patients. | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 31, 2017

Primary Completion Date

July 24, 2018

Study Completion Date

February 15, 2019

Conditions

Primary MyelofibrosisPost-Polycythemia Vera-MyelofibrosisPost-Essential Thrombocythemia Myelofibrosis

Interventions

DRUG

ruxolitinib

Ruxolitinib was supplied in 5 mg tablets to be taken orally approximately 12 hours apart (morning and night)

Trial Locations (20)

1413

Novartis Investigative Site, Sofia

1756

Novartis Investigative Site, Sofia

2060

Novartis Investigative Site, Antwerp

3000

Novartis Investigative Site, Leuven

15706

Novartis Investigative Site, Santiago de Compostela

34093

Novartis Investigative Site, Istanbul

40138

Novartis Investigative Site, Bologna

41380

Novartis Investigative Site, Kocaeli

50134

Novartis Investigative Site, Florence

90127

Novartis Investigative Site, Palermo

125167

Novartis Investigative Site, Moscow

129110

Novartis Investigative Site, Moscow

185019

Novartis Investigative Site, Petrozavodsk

A-1090

Novartis Investigative Site, Vienna

V5Z 1M9

Novartis Investigative Site, Vancouver

06120

Novartis Investigative Site, Halle S

115 27

Novartis Investigative Site, Athens

113-8431

Novartis Investigative Site, Bunkyo Ku

08036

Novartis Investigative Site, Barcelona

03010

Novartis Investigative Site, Alicante